Immune phenotype of chronic liver disease by Czaja, JA et al.
Immune Phenotype of Chronic Liver Disease
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Immune disorders in chronic liver disease may re¯ ect common host propensitie s or disease-
speci® c factors. Our aim was to determine the principal base s for these expre ssions. Four
hundre d ® fty-one patients with various chronic live r diseases were assessed prospectively for
concurrent immune disorders. Individuals with immune diseases were more frequently
women (73% vs 60% , P 5 0.02) and they had HLA DR4 more often than counterparts with
other HLA (46% vs 23% , P 5 0.000008) . The association between HLA DR4 and immune
disease was apparent within individual live r diseases and within different categorie s of liver
disease . Women with HLA DR4 had a highe r frequency of immune disease than women
without HLA DR4 (52% vs 22% , P # 0.000001) , and they also had immune diseases more
commonly than DR4-positive men (52% vs 31% , P 5 0.03) . DR4-positive men, however, had
highe r frequencie s of immune disease than DR4-negative men, especially in the nonimmune
types of liver disease (26% vs 4% , P 5 0.002) . We conclude that HLA DR4 and female
gender constitute an immune phenotype that is an important basis for autoimmune expre s-
sion in chronic liver disease .
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Immune-mediated nonhepatic diseases, including au-
toimmune thyroiditis, Graves’ disease , Sjogre n’ s syn-
drome , and ulce rative colitis, are frequently found in
type 1 autoimmune hepatitis (1, 2). A host-dependent
genetic predisposition for these manife stations has
been propose d and an association has been described
with HLA DR4 (2± 4). Similar immune manife sta-
tions occur in other types of chronic live r disease and
an association with HLA DR4 has also been found
(5± 8). These ® ndings sugge st the existence of an
ª immune phenotype º that is host-dependent and not
disease-speci® c.
Immune response genes reside within the major
histocompatib ility complex (MHC) in experimental
animals, and there is circumstantial evidence that
these genes exist in humans (9). Concurrent immune
diseases in various chronic liver diseases could re¯ ect
this genetic predisposition. The liver disease may
release or modify self-antige ns that trigge r the im-
mune expre ssion or it may present to the genetically
predispose d host extrinsic antige ns that cross-react
with self-antige ns (molecular mimicry) (10) . Cyto-
kine s, such as endogenous inte rferon, may also alte r
immunoreactivity in a nonse lective fashion (11) and
the liver disease itse lf may impair important immu-
nomodulatory functions, such as suppre ssor T-cell
activity, in relation to its severity (12) .
HLA DR4 may have an antige n-binding groove
that facilitate s the presentation of self-antige ns or
foreign antige ns that resemble self-antigens to circu-
lating immunocyte s (13) . This presentation may in
turn stimulate an immunoreactivity that results in the
expre ssion of an immune disease . Not all concurrent
immune diseases, however, have an association with
HLA DR4 and not all patients with HLA DR4 have
immune manifestations (3, 7). Furthermore , many
immune diseases in type 1 autoimmune hepatitis and
other chronic liver disorde rs have HLA associations
Manuscript rece ived February 26, 1998; accepte d April 29, 1998.
From the Division of Gastroente rology and Hepatology, Mayo
Clinic and Mayo Foundation, Rochester, Minnesota; the Depart-
ment of Medicine III, University of Coimbra, Coimbra, Portugal;
and the Department of Laboratory Medicine and Pathology, Mayo
Clinic and Mayo Foundation, Rochester, Minnesota.
Presented in part at the Meeting of the American Association for
the Study of the Liver Diseases, November 11, 1997, Chicago, Illinois.
Address for reprint requests: Dr. Albert J. Czaja, Mayo Clinic,
200 First Street S.W., Rochester, Minnesota 55905.
Digestive Diseases and Sciences, Vol. 43, No. 9 (September 1998), pp. 2149 ± 2155
2149Digestive Diseases and Sciences, Vol. 43, No. 9 (September 1998)
0163-2116/98/0900-2149$15.00/0 Ñ 1998 Plenum Publishing Corporation
outside the context of the liver disease , and they are
not HLA DR4-related (7). In all these instances,
factors other than HLA DR4 must be invoked to
explain the propensity for immune expre ssion, and
they may be host-re lated, disease-speci® c, host- and
disease-related, or coincidental.
In this study, we extend our hypothe sis of an im-
mune phenotype based on HLA DR4 to determine
other important host-dependent and disease-speci® c
factors that affect the frequency of immune expre s-
sion in chronic live r disease. We determine the dis-
ease-speci® city of the immune ® ndings, and we eval-
uate the importance of differences in disease activity,
stage, and nature on their occurrence . Lastly, we
assess the role of gender on immune expression in
patients with and without HLA DR4, and we deter-
mine for the ® rst time the impact of these host-
dependent factors on immune expre ssion in different
types of chronic live r disease. By counterbalancing
host- and disease-related feature s, the propensitie s
for immune expression are de ® ned and the bases for
differences in the prevalence of immune phenomena
in various chronic liver diseases described.
MATERIALS AND METHODS
Study Populations. Four hundred ® fty-one patients with
well-established chronic liver disease were studied prospec-
tively for concurrent immune diseases. Each patient was
assessed by one investigator (A.J.C.) in accordance with a
prede ® ned protocol that systematically evaluated etiologic
factors for the liver disease (viral, drug, genetic, alcoholic,
and autoimmune bases), DR human leukocyte antigens
(HLA), associated immune diseases, conventional labora-
tory indices of in¯ ammatory activity and disease severity,
and histologic ® ndings (1± 7). The patients were chosen
from 502 individuals who had been evaluated similarly but
in whom the database for classi® cation and analysis was
incomplete or nondiagnostic. Our study had been approved
by the Institutional Review Board of the Mayo Clinic as
part of a program project grant.
One hundred seventy-seven patients had type 1 autoim-
mune hepatitis (39% ); 5 patients had autoimmune cholan-
gitis (1% ); 32 patients had primary biliary cirrhosis (7% ); 21
had primary sclerosing cholangitis (5% ); 21 had chronic
hepatitis B (5% ); 133 had chronic hepatitis C (29% ); 14 had
chronic alcoholic liver disease (3% ); 30 had nonalcoholic
steatohepatitis (7% ); and 18 had cryptogenic chronic hep-
atitis (4% ) (Table 1). The diagnosis of autoimmune hepa-
titis required satisfaction of the criteria promulgated by the
International Autoimmune Hepatitis Group (14), and se-
ropositivity for smooth muscle antibodies (SMA) and/or
antinuclear antibodies (ANA) was required for the desig-
nation of type 1 disease (15) . The diagnoses of the other
conditions were based on conventional clinical criteria (7).
Patients were further classi® ed as having immune type
and nonimmune type chronic liver disease based on puta-
tive pathogenic mechanisms. Two hundred thirty-® ve pa-
tients (52% ) were categorized as having immune type dis-
orders, including 177 patients with type 1 autoimmune
hepatitis, 5 patients with autoimmune cholangitis, 32 patients
with primary biliary cirrhosis, and 21 patients with primary
sclerosing cholangitis. Two hundred sixteen patients were cat-
egorized as having nonimmune type disorders (48% ), includ-
ing 21 patients with chronic hepatitis B, 133 patients with
chronic hepatitis C, 14 patients with chronic alcoholic liver
disease, 30 patients with nonalcoholic steatohepatitis, and
18 patients with cryptogenic chronic hepatitis.
Patients were also classi® ed into viral and nonviral cate-
gories depending on the presumed etiology of their disease.
One hundred ® fty-four patients (34% ) had either chronic
hepatitis B (21 patients) or chronic hepatitis C (133 pa-
tients), and they were designated as having viral disease.
Two hundred ninety-seven patients (66% ) lacked serologic
markers of viral infection, and they were designated as
having nonviral disease.
Concurren t Immune Diseases. Concurrent nonhepatic
disorders of an immunologic nature were sought in a uni-
form fashion in each patient in accordance with previously
published guidelines (1± 7). The presence of thyromegaly,
synovitis, colitis, and skin lesions were recorded systemati-
cally. The sensitive thyroid-stimulating hormone leve l and
thyroid antibodies, including thyroglobulin and microsomal
antibodies, were determined in each individual. If clinical
history, physical examination, or laboratory ® ndings revealed
abnormalities, additional studies were performed as indicated.
The diagnosis of autoimmune thyroiditis required the
presence of thyroid dysfunction and seropositivity for one
or both thyroid antibodies (16) . Hyperthyroidism, as indi-
cated by hyperthyroxemia and suppressed sensitive thyroid-
stimulating hormone leve l, in conjunction with thyro-
megaly, connoted Graves’ disease (17). An historical basis
for the diagnosis was accepted if thyroid ablation had been
undertaken previously. Other nonthyroid diseases were des-
ignated as immunologic in nature if their putative patho-
genesis included immune mechanisms (4) . In this regard,
insulin-dependent diabetes mellitus was included among
the diagnostic considerations (18).
Forty patients (9% ) satis® ed criteria for autoimmune
thyroiditis. Twenty-three patients had ulcerative colitis; 11
had Graves’ disease ; 10 had synovitis; 6 had insulin-
dependent diabetes; 6 had cutaneous vasculitis; 5 had
TABLE 1. FREQUENCY OF CONCURRENT IMMUNE DISEASES IN
CHRONIC LIVER DISEASE
Liver diagnosis
Total
patients
(N)
Patients with
immune diseases*
[N (% )]
Type 1 autoimmune hepatitis 177 68 (39)
a,b,c,d
Autoimmune cholangitis 5 1 (20)
Primary biliary cirrhosis 32 9 (28)
Primary sclerosing cholangitis 21 15 (71)b
Chronic hepatitis B 21 4 (19)
Chronic hepatitis C 133 29 (22)a
Alcoholic disease 14 1 (7)
c
Nonalcoholic steatohepatitis 30 7 (23)
Cryptogenic hepatitis 18 2 (11)
d
* Signi® cantly different from type 1 autoimmune hepatitis at levels
of
a
P 5 0.002; b P 5 0.005; and c,d P 5 0.02.
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asthma; 4 had Crohn’s disease ; 3 had idiopathic thrombo-
cytopenic purpura; 3 had Sjogren’s syndrome; 3 had kera-
toconjunctivitis sicca; 3 had rheumatoid arthritis; 2 had
dermatitis herpetiformis; 2 had erythema nodosum; 2 had
lichen planus; 2 had mononeuritis multiplex; 2 had systemic
lupus erythematosis; and 1 each had lymphocytic colitis,
myositis, glomerulonephritis, pernicious anemia, Coomb’s-
positive hemolytic anemia, pericarditis, pulmonary ® brosis,
systemic sclerosis, or vitiligo. The total number of individ-
uals with concurrent immune disorders was 136 (30% ).
Immunoserologic Assays for Liver-Related Autoan tibod-
ies. Patients were screened at presentation for the presence
of SMA, ANA, antibodies to liver/kidney microsome type 1
(anti-LKM1), and antimitochondrial antibodies (AMA) by
indirect immuno¯ uorescence on murine kidney and stom-
ach sections as described previously (19 ± 22) . A serum titer
of 1:40 or higher was considered positive for SMA, ANA,
and AMA. A serum titer of 1:10 or higher was considered
positive for anti-LKM1.
Four hundred forty-eight patients (99% ) were tested for
SMA; 449 patients (99% ) were tested for ANA; 446 pa-
tients (99% ) were tested for AMA; and 421 patients (93% )
were tested for anti-LKM1.
Immunoserologic Assays for Thyroid Antibod ies. Thyro-
globulin and microsomal thyroid antibodies were sought in
all patients by standard techniques (23± 25). A titer of at
least 1:100 was considered positive. Forty-four patients
(10% ) had thyroglobulin antibodies, and 114 patients
(25% ) had microsomal antibodies. Forty patients (9% ) had
both antibodies and seventy-eight patients (17% ) had only
one. Of the 40 patients with autoimmune thyroiditis, 24
patients were seropositive for only one thyroid antibody
(thyroglobulin antibodies in one patient and microsomal
antibodies in 23 patients) and 16 were seropositive for both
thyroid antibodies.
Histologic Assessments. Liver tissue was obtained by
needle biopsy in 406 patients (90% ) at the time of presen-
tation. Of the 45 patients who did not undergo liver biopsy
examination, 27 had chronic hepatitis C, 6 had chronic
alcoholic liver disease, 4 had primary biliary cirrhosis, 3 had
cryptogenic chronic hepatitis, 2 had primary sclerosing
cholangitis, 2 had chronic hepatitis B, and 1 had type 1
autoimmune hepatitis. In each instance, the clinical diag-
nosis was judged secure without histologic con® rmation and
the patients were included in the analysis.
Specimens were interpreted under code, and the diagno-
sis of cirrhosis required ® brosis and the presence of a
complete regenerative nodule. One hundred patients who
were biopsied (25% ) had cirrhosis.
Virologic Assessments. All patients were tested for anti-
bodies to hepatitis C virus (anti-HCV) by a second gener-
ation ELISA (Ortho Diagnostic Systems, Inc., Raritan, New
Jersey) . Hepatitis B surface antigen (HBsAg) was also
sought in each patient by ELISA (Abbott Laboratories,
North Chicago, Illinois).
HLADR3 and DR4 Determination s. Four hundred twen-
ty-two patients (94% ) were evaluated for the class II (DR
locus) antigens. All patients were caucasoid. A standard
microlymphocytotoxicity technique was used and multiple
locally derived and commercially available sera de ® ned the
DR3 and DR4 speci® cities as described elsewhere (2, 3).
Restriction fragment length polymorphism (RFLP) was
used to de ® ne DR3 and DR4 status in 269 patients (26) and
polymerase chain reaction with sequence speci ® c primers
(PCR-SSP) was used to de ® ne DR3 and DR4 status in 107
patients (27). RFLP and PCR-SSP split DR3 into DR17
and DR18, but for the purposes of this study all ® ndings
were expressed as DR3.
Statis tical Analyses. Dichotomous variables were com-
pared by the Fisher exact test. The unpaired t test was used
to evaluate the signi® cance of differences in means for
continuous variables. The Mann-Whitney test was used to
compare nonparametric variables in independent samples.
HLA DR3 and DR4 are known risk factors for autoimmune
expression, and only the frequencies of these antigens were
analyzed in our study population. Since the variables for
comparison had been formulated a priori and then assessed
systematically in each study group, an unadjusted P value of
0.05 was used to determine statistical signi® cance. Data are
presented as the mean 6 SEM in tables and text.
RESULTS
Immune Features and Type of Liver Disease. Pa-
tients with type 1 autoimmune hepatitis had a highe r
frequency of concurrent immune disease than pa-
tients with other chronic live r diseases, especially
those with chronic hepatitis C, alcoholic liver disease,
and cryptogenic chronic hepatitis (Table 1). Only
patients with primary sclerosing cholangitis differed in
this regard mainly because of the ir high frequency of
concurrent in¯ ammatory bowe l disease (Table 1).
Type of Immune Disease and Liver Diagnosis. Ex-
trahepatic immune manife stations occurred in all
types of chronic liver disease regardle ss of presumed
nature (Table 2). Thyroid disease occurred most com-
monly, affecting 51 patients (11% ) eithe r as autoim-
mune thyroiditis (40 patients) or Graves’ disease (11
patients). Only the small number of patients with
alcoholic liver disease (14 patients) lacked this man-
ifestation (Table 2).
Autoimmune thyroiditis (15% vs 5% , P 5 0.0006)
and Graves’ disease (5% vs 1% , P 5 0.008) were each
more frequent in type 1 autoimmune hepatitis than in
other conditions, and both forms of autoimmune thy-
roid disease occurred more often in type 1 autoim-
mune hepatitis than in chronic hepatitis C (20% vs
7% , P 5 0.001) . Vasculitis was common in chronic
hepatitis C, but its occurrence was not highe r than
that in other chronic live r disorde rs, including type 1
autoimmune hepatitis (4% vs 1% , P 5 0.09) .
Immune Features and Clin ical Findings. Patients
with concurrent immune diseases were more com-
monly women than patients without these manife sta-
tions, and they also had SMA more frequently (Table
3). As recognized previously, individuals with concur-
rent immune diseases were DR4-positive more often
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than patients without this antige n (Table 3). In con-
trast, concurrent immune diseases were not associ-
ated with HLA DR3, age , the presence of cirrhosis, or
the laboratory indices of live r in¯ ammation or immu-
noreactivity (Table 3).
Immune Featu res and Effects of Gender With in
and Between Diagn ostic Categories. Women had im-
mune-type chronic live r diseases (62% vs 33% , P ,
0.0001) more commonly than men, and men had
viral-type chronic live r diseases (50% vs 25% , P ,
0.0001) more frequently than women. In each diag-
nostic category and in each gender, immune diseases
occurred more commonly in association with HLA DR4
(Table 4).
Women had a higher frequency of concurrent im-
mune diseases than men in viral type and nonviral
TABLE 4. IMMUNE FEATURES AND EFFECTS OF GENDER WITHIN
DIAGNOSTIC CATEGORIES
Category of liver
disease
Immune features
Men
[N (% )]
Women
[N (% )]
Immune type
DR4 1 4/8 (50) 36/72 (50)d*
DR4 2 15/39 (38) 27/94 (29)d
Nonimmune type
DR4 1 9/34 (26)b,e 20/35 (57) a,e
DR4 2 3/70 (4)b 9/70 (13) a
Viral
DR4 1 10/77 (13) f 21/77 (29) f,g
DR4 2 2/51 (4) 5/48 (10) g
Nonviral
DR4 1 5/16 (31) 40/83 (48) c
DR4 2 16/58 (28) 31/116 (27) c
* Signi® cantly different from each other at leve l of
a
P 5 0.000004;
b
P 5 0.002; c P 5 0.003; d P 5 0.006; e P 5 0.01; and f,g P 5 0.02.
TABLE 2. TYPES OF CONCURRENT IMMUNE DISEASE ACCORDING
TO LIVER DISEASE
Liver disease Immune disease N (% )
Type 1 autoimmune Autoimmune thyroiditis 26 (15)
hepatitis Ulcerative colitis 11 (6)
Graves’ disease 9 (5)
Synovitis 3 (2)
Asthma 2 (1)
Systemic lupus
erythematosus 2 (1)
Dermatitis herpe tiformis 1 (1)
Coomb’s anemia 1 (1)
Crohn’s disease 1 (1)
Diabete s mellitus 1 (1)
Erythema nodosum 1 (1)
Pernious anemia 1 (1)
Rheumatoid arthritis 1 (1)
Others* 8 (4)
Autoimmune cholangitis Graves’ disease 1 (20)
Primary biliary cirrhosis Keratoconjunctivitis sicca 3 (10)
Autoimmune thyroiditis 1 (3)
Diabete s mellitus 1 (3)
Lichen planus 1 (3)
Sjogren’s syndrome 1 (3)
Synovitis 1 (3)
Vitiligo 1 (3)
Primary sclerosing Ulcerative colitis 10 (47)
cholangitis Crohn’s disease 3 (14)
Asthma 1 (5)
Autoimmune thyroiditis 1 (5)
Chronic hepatitis B Autoimmune thyroiditis 1 (5)
Glomerulonephritis 1 (5)
Rheumatoid arthritis 1 (5)
Ulcerative colitis 1 (5)
Chronic hepatitis C Autoimmune thyroiditis 8 (6)
Synovitis 5 (4)
Vasculitis 5 (4)
Asthma 2 (1)
Dermatitis herpe tiformis 1 (1)
Diabete s mellitus 1 (1)
Erythema nodosum 1 (1)
Graves’ disease 1 (1)
Idiopathic thrombocytopenia 1 (1)
Lymphocytic colitis 1 (1)
Neuritis 1 (1)
Rheumatoid arthritis 1 (1)
Ulcerative colitis 1 (1)
Alcoholic disease Diabete s mellitus 1 (7)
Nonalcoholic Diabete s mellitus 2 (7)
steatohepatitis Autoimmune thyroiditis 1 (3)
Idiopathic thrombocytopenia 1 (3)
Pericarditis 1 (1)
Sjogren’s syndrome 1 (1)
Synovitis 1 (1)
Cryptogenic hepatitis Autoimmune thyroiditis 2 (11)
* Others 5 single cases of iritis, idiopathic thrombocytopenic pur-
pura, myositis, mononeuritis multiplex, pulmonary ® brosis, sys-
temic sclerosis, Sjogren’s syndrome , and vasculitis.
TABLE 3. FEATURES AT PRESENTATION OF PATIENTS WITH AND
WITHOUT IMMUNE DISEASES*
Clinical features
Immune diseases
Present
(N 5 136)
Absent
(N 5 315)
Age (yr) 49 6 1 48 6 1
Male :female 37:99
d
123:192
d
AST (nl: # 31 units/liter) 292 6 30 237 6 18
Bilirubin (nl: # 1.1 mg/dl) 2.9 6 0.4 2.3 6 0.2
g -globulin (nl: 0.7± 1.6 g/dl) 2.4 6 0.1 2.2 6 0.1
Immunoglobulin G
(nl: 700± 1500 mg/dl) 2191 6 105 1934 6 63
SMA $ 1:40 61/135 (45) c 97/313 (31) c
ANA $ 1:40 64/135 (47) 141/314 (45)
AMA $ 1:40 17/135 (13) 34/311 (11)
Cirrhosis 31/123 (25) 69/283 (24)
DR3 1 /DR4 2 28/123 96/299
DR4 1 /DR3 2 53/123 b 63/299 b
DR3 1 /DR4 1 16/123 e 17/299 e
DR4 1 /DR3 2 or DR3 1 69/123 a 80/299 a
DR3 1 /DR4 2 or DR4 1 44/123 113/299
* Numbers in parentheses are percentage s. Signi® cantly different
from each other at leve ls of
a
P , 0.000001; b P 5 0.000008;
c
P 5 0.005; and d,e P 5 0.02. AST 5 serum aspartate amino-
transferase level; SMA 5 smooth muscles antibodies; ANA 5
antinuclear antibodies; AMA 5 antimitochondrial antibodies.
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type chronic live r diseases, indicating the potentiating
effect of female gender in each disease category (Ta-
ble 4). Furthermore , women who were HLA DR4
positive had highe r frequencies of concurrent im-
mune feature s in all disease categorie s than female
counterparts who were HLA DR4 negative (52% vs
22% , P # 0.000001) , and they also had immune
diseases more commonly than DR4-positive men
(52% vs 31% , P 5 0.03) (Table 4). Similarly, DR4-
positive men had concurrent immune diseases in all
dise ase categorie s more commonly than DR4-
negative men, especially in the live r diseases of a
nonimmune nature (26% vs 4% , P 5 0.002) (Table 4).
DR4-positive men had similar frequencie s of con-
current immune disease regardle ss of disease cate -
gory (Table 4), whereas DR4-positive women with
nonviral types of chronic live r disease had a greater
occurrence of immune manifestations than DR4-
positive women with viral types of chronic live r dis-
ease (48% vs 29% , P 5 0.009) (Table 4). These
® ndings indicate d that among men the HLA pheno-
type was more important for immune expression than
the nature of the live r disease , whereas among women
the nature of the live r disease as well as the HLA
phenotype were important (Table 4).
DISCUSSION
Our study indicate s that concurrent immune dis-
eases are present in all types of chronic liver disease
and that an individual immune manife station does
not compel a particular liver diagnosis. Autoimmune
thyroid diseases occurred more frequently in type 1
autoimmune hepatitis, but they were present in all of
the diagnostic categories except alcoholic liver dis-
ease. In this latter condition, the prevalence of autoim-
mune thyroiditis and/or Graves’ disease may have been
affected by the small number of patients and their male
predominance (12 of the 14 patients were men).
Individuals deve loping extrahepatic immune disor-
ders were characterized mainly by the ir female gen-
der and the presence of HLA DR4. Women have long
been known to have a greater immunoreactivity and
propensity for autoimmune manife stations than men
(28, 29) , and this predisposition was evident in all
forms of chronic live r disease included in our study
(Tables 3 and 4). Women deve lop higher serum im-
munoglobulin levels than men after exposure to a
common antigen load (30 ± 32) , and they have highe r
natural frequencie s of various autoantibodie s (33,
34) . Estrogens promote B-cell-dependent immune-
complex-mediated disease (35) ; they modulate re-
lease of tumor necrosis factor from macrophage s,
which may in turn affect monocyte cytotoxicity and
the chemotaxis of leukocyte s (36) ; they inhibit sup-
pressor T-cell function and thereby activate the im-
mune response (37) ; they affect CD4
1
T-lymphocyte
activity, especially antige n-speci® c cytotoxic T lym-
phocyte response (38) ; and they in¯ uence cytokine
production, especially that of interleukin-1 and inte r-
feron- g (39, 40) . An immunomodulatory gene on the
X chromosome has also been propose d (41, 42) , and
the increased immunoreactivity in women may re¯ ect
a ª double dose º of this gene . Furthermore , othe r
hormones, including androgens (43) and prolactin
(44) , may affect the vigor of the immune response by
counterbalancing estrogen effects (43, 45) or by en-
hancing antige n processing through direct trophic
actions on the immunocyte s (44) .
Importantly, female gender alone was insuf® cient
to distinguish patients with and without immune man-
ifestations and HLA DR4-negative men and women
had similar occurrences of immune disease regardle ss
of the liver diagnosis (Table 4). Both female gender
and HLA DR4 positivity were required to enhance
the propensity for immune expre ssion, and these ® nd-
ings suggested that female hormone s and/or immu-
noregulatory genes (39, 41± 43) potentiated the im-
munoreactivity to self-antigens displayed by HLA DR4.
Interestingly, HLA DR4-positive men had greater fre-
quencies of immune manifestations than HLA DR4-
negative men in all categories of liver disease, especially
in the nonimmune types (Table 4). This observation
indicated that HLA DR4 was an important risk factor
for immune expression independently of gender.
The role of the liver disease in facilitating immune
expre ssion is unknown. The occurrence of immune
disorde rs was not associated with conventional indi-
ces of live r in¯ ammation and function or with the
presence of cirrhosis (Table 3). In HLA DR4-positive
men, immune manife stations occurred with similar
frequency in all categorie s of live r disease, and there
was no etiologic predilection for a particular immune
feature. In these individuals, the immune disorde r
may have been coincidental to the liver disease or the
live r disease may have had a facilitative effect that was
not disease-speci® c. In this regard, the liver condition
per se may have disturbed cytokine production (11) or
suppressor T-cell function (12) .
In contrast, HLA DR4-positive women who had
nonviral types of chronic live r disease had a greater
frequency of immune diseases than counte rparts with
viral types of chronic live r disease. In these individu-
als, the nature of the liver disease may have in¯ u-
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enced the immune propensity by affecting the type
and/or amount of autoantige ns processed. Alterna-
tive ly, the susceptibility factors for both the nonviral
live r diseases and the immune feature s may have
been similar and their cluste ring may have re¯ ected
the pluripote nt nature of the risk factors (2± 4, 7).
Alle les within the DR4 loci encode particular
amino acid sequences in the DR b polypeptide that
determines the ability of each class II molecule to
bind and present antigens to T cells (46, 47) . Similar
antige n-pre senting mechanisms in different chronic
live r diseases may facilitate expression of the same
immune manifestation. Homologie s between differ-
ent trigge ring antigens are also required. Mole cular
mimicry has already been recognized between certain
viral genomes and autoantige ns (10, 48) , and it is
possible that some autoantige ns have homologous
epitope s that trigger similar clinical manife stations in
different live r diseases. The female gender may pro-
mote this antige nic cross-reactivity by heightening
immune responsive ness (28, 29, 39, 43) .
In our study, HLA DR4 de ® ned a general propen-
sity for immune expre ssion rather than a susceptibility
to a particular disease , and this propensity was en-
hanced by female gender. Since many of the concur-
rent immune diseases had HLA associations other
than HLA DR4, the ir clustering in chronic liver dis-
ease in association with HLA DR4 sugge sted that
more than one alle le was responsible for the ir expre s-
sion (49) . In the context of chronic live r disease, HLA
DR4 may be a secondary, but necessary, co-factor for
the deve lopment of concurrent immune diseases (49) .
The majority of immune disorde rs described in our
patients were autoantige n driven (Table 2) (8). Other
immune disorde rs may be viral antige n driven, and
these conditions , including those associate d with
cryoglobuline mia, may have greater disease speci® city
than host dependence (8, 50, 51) . Cryoglobuline mia
was not routine ly sought in our patients, and we
cannot determine if immune complex diseases have the
same risk factors for expression as conditions mediated
mainly by immunocyte s. Future studies must categorize
the immune manifestations according to putative patho-
genic mechanisms and de ® ne the risk factors associated
with each type of immune expression.
In summary, concurrent immune diseases occur in
all types of chronic live r disease , and they do not
connote a particular liver diagnosis. Female gender
affects the propensity for immune expression, espe-
cially in patients with HLA DR4, and these host-
related factors constitute an immune phenotype . Dis-
ease factors in¯ uence the nature and the frequency of
immune expre ssion in some patients, especially in
HLA DR4-positive women with nonviral types of
chronic liver disease, but the propensity for immune
expre ssion is mainly host-re lated.
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